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Abstract – The objective of this study was to evaluate the effect of a commercial vaccine adjuvant
on the clinical and pathological outcome of PCV2 experimentally infected 8 to 9-week-old
conventional pigs. Forty-four pigs were divided into four groups: non-infected control pigs, pigs that
received a vaccine adjuvant, pigs inoculated with PCV2, and pigs inoculated with PCV2 together
with the vaccine adjuvant. Infection was monitored until 69 days post-inoculation (PI). Some PCV2
inoculated pigs had hyperthermia, but no other clinical signs were recorded. No characteristic
PMWS gross or microscopic lesions were observed in any of the pigs. PCV2 DNA was detected in
lymphoid tissues by in situ hybridisation in 6 PCV2 inoculated pigs on day 69 PI. All PCV2
inoculated pigs seroconverted between days 21 and 49 PI, shortly after viremia detection. Moreover,
viremia was detected between days 7 and 69 PI using PCR. A peak of the virus load was detected
by real-time quantitative PCR between days 14 and 21 PI. There were no significant differences in
the proportion of PCV2 positive serum and in the viral load between PCV2 and PCV2 + adjuvant
inoculated pigs. Although PMWS was not reproduced in neither PCV2 nor PCV2 + adjuvant
inoculated pigs, viremia detection and seroconversion indicated that all PCV2 inoculated pigs
developed a chronic long-term asymptomatic infection. An increase of PCV2 replication was not
observed in pigs inoculated with the adjuvant. These results indicate that the principle of
immunostimulation may not be applicable under the experimental conditions used, suggesting that
not all adjuvants used in commercial vaccines are capable of triggering mechanisms for PMWS
development.  
porcine circovirus type 2 (PCV2) / pigs / vaccine adjuvant / real-time quantitative PCR /
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1. INTRODUCTION
Porcine circoviruses include two anti-
genically and genomically distinct viruses
of swine, namely porcine circovirus type 1
(PCV1) and type 2 (PCV2), assigned to the
Circoviridae family. The virions are spher-
ical, non-enveloped with an icosahedral
symmetry. The genome consists of a single-
stranded molecule of circular DNA [18,
25]. PCV2 is recognised as the cause of a
clinical condition of swine named post-
weaning multisystemic wasting syndrome
(PMWS) [2, 7, 9]. This disease mainly
affects 5 to 12 week-old pigs, and is clini-
cally characterised by growth retardation,
skin pallor, dyspnea, and enlargement of
the inguinal lymph nodes. Main gross find-
ings include non-collapsed lungs, and
generalised lymphadenopathy. Histologi-
cal characteristic lesions of PMWS consist
of lymphocyte depletion and histiocytic
infiltration, often with multinucleate giant
cells and amphophilic intracytoplasmatic
inclusion bodies in lymphoid tissues [7,
23]. Histological lesions are systematically
associated with PCV2 antigen and/or
nucleic acid [23]. 
Koch postulates have been fulfilled for
PCV2 as the primary cause of PMWS [2, 7,
10]. However, the severe clinical expres-
sion observed in field cases has been diffi-
cult to reproduce experimentally [1], sug-
gesting that the disease is probably of
multifactorial aetiology and/or that not all
hosts are susceptible to the development of
the disease. Experimentally, a synergistic
relationship is observed when PCV2 is co-
inoculated with porcine parvovirus (PPV)
or porcine reproductive and respiratory
syndrome virus (PRRSV), resulting in a
more severe expression of PMWS [2, 3, 9,
11, 24]. These studies did not elucidate
the synergistic mechanism between those
viruses and PCV2, but it is suggested that
the activation of the cells from the mono-
cyte/macrophage lineage by PPV and
PRRSV could support an increase of PCV2
replication [2, 3].
The hypothesis of the immune system’s
stimulation by vaccines and/or vaccine
adjuvants, as the key event in PMWS devel-
opment is gaining acceptance, supported by
some field and laboratory trials [5, 12, 14].
The use of Mycoplasma hyopneumoniae
vaccines in nursery pigs together with
PCV2 inoculation seems to enhance the
severity of clinic and pathologic expression
of the wasting disease [4, 14]. Moreover,
severe PMWS expression is highly preva-
lent when using PCV2 infected 3-day-old
gnotobiotic piglets immune stimulated with
keyhole limpet haemocyanin antigen emul-
sified in incomplete Freund adjuvant
(KLH/ICFA) with or without intraperito-
neal glycan [12]. However, in the same
experimental trial the use of the same
immunostimulant injected IM in the neck
only induced a subclinical infection [12].
Moreover, controversial results have also
been observed when KLH/ICFA is admin-
istered to 3-week-old SPF pigs [15]. In evi-
dence of these facts, the importance of vac-
cine adjuvants as a triggering factor of
PMWS, as well as the mechanism of PCV2
replication enhancement, need to be further
investigated.
The objective of this study was to eval-
uate the effect of a commercial vaccine
adjuvant on PMWS development and
PCV2 replication in 8 to 9-week-old con-
ventional pigs, an age at which PMWS is
usually observed under field conditions. 
2. MATERIALS AND METHODS
2.1. Animals and husbandry 
Forty-two crossbreed piglets were deliv-
ered from seven sows coming from a
conventional 50-sow, farrow-to-finish oper-
ation, free of infection with PPV, PRRSV,
Aujeszky disease virus, swine influenza
virus, transmissible gastroenteritis coro-
navirus, porcine respiratory coronavirus
and Actinobacillus pleuropneumoniae, Pas-
teurella multocida, Bordetella bronchisep-
tica and swine erysipelas. PMWS-like
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clinical signs were never observed on the
farm. However, the farm was known to be
enzootically infected with PCV2 based on
previous serologic analysis. The piglets
were weaned at 2 weeks of age, and moved
to level 2 biosecurity facilities. Thereafter,
the piglets were ear tagged and weekly
monitored for decrease of PCV2 maternal
antibody titres by IPMA [21]. At approxi-
mately 8–9 weeks of age, when PCV2 anti-
body titres were low (≤1:320), the pigs
were divided into four groups and housed
in different isolated rooms. The animals
were fed ad libitum with a conventional
swine growth-diet and tap water.
2.2. Viral inoculum 
Swine kidney (SK) cells were inoculated
with a tissue homogenate prepared from tis-
sues (lymph nodes, spleen, liver and kid-
ney) obtained from a PMWS affected pig.
After two serial passages, culture superna-
tants were recovered, clarified by centrifu-
gation at 650 × g, and further ultracentri-
fuged at 100 000 × g. The viral pellet was
resuspended in DMEM, titrated in non-
infected SK cells (104.7 50% tissue culture
infective dose (TCID50)/mL), aliquoted
and frozen at –80 °C until used. This inoc-
ulum was shown to be free of PRRSV, PPV,
and PCV1 by PCR. 
2.3. Experimental design 
Selected pigs were bled, weighed and
rectal temperatures were taken before chal-
lenge. Fourteen pigs were intranasally inoc-
ulated with 2.5 mL (total dose: 105 TCID50/
pig) of PCV2 inoculum each (PCV2-
group). Another group of 16 pigs was iden-
tically inoculated with PCV2 and intramus-
cularly injected with 2 mL of an adjuvant
in one side of the neck (PCV2 + ADJ-
group). The adjuvant (ADJ), currently used
in commercial vaccines (Fort Dodge Vet-
erinaria S.A., Vall de Bianya, Girona,
Spain), contained manitol oleic ester (Mon-
tanide 888) plus poliethoxi eter oleate
(Simusol 5100) emulsified in white mineral
oil (Marcol 52). Six pigs were intranasally
inoculated with 2.5 mL of PBS (control-
group), and the other six pigs were addition-
ally injected with vaccine adjuvant as pre-
viously described (ADJ-group). 
Clinical monitoring was done daily, and
the rectal temperature was taken every
2 days until day 23 post-inoculation (PI),
and thereafter at weekly intervals. Body
weight and blood samples were taken
weekly until the termination of the experi-
ment. Pigs were euthanised at 69 days PI
(DPI) (19 weeks of age) with an overdose
of intravenous pentobarbital, followed by
ex-sanguination. A complete post-mortem
examination was performed in all animals,
and tissue samples (lung, tonsil, inguinal
and mesenteric lymph nodes, liver, kidney,
spleen, ileum, and nasal turbinates) col-
lected and fixed by immersion in 10% buff-
ered formalin. This study met the standards
of the European Guidelines for Animal
Welfare and the study protocol was
approved by the Comitè Ètic d’Experiment-
aciò Animals de Fort Dodge Veterinaria
S.A., Girona, Spain (Ethics Committee of
Animal Experimentation of Fort Dodge
Veterinaria, S.A., Girona, Spain) and the
Comissió d’Experimentaciò Animal del
Departament d’Agricultura, Ramaderia i
Pesca de la Generalitat de Catalunya,
Barcelona, Spain (Committee of Animal
Experimentation of Agriculture, Livestock
and Fisheries Department of the Catalan
Government, Barcelona, Spain). 
2.4. Serology 
PCV2 and PCV1 antibodies were deter-
mined by a previously described IPMA
technique [21]. Sera dilutions were from
1:20 to 1:20480, making serial four-fold
dilutions. For statistical analyses, serologic
results were grouped as negative or posi-
tive with low titre (1:20 to 1:80), interme-
diate titre (1:320 to 1:1280), and high titre
(1:5120 to 1:20480). The pigs were inocu-
lated with PCV2 when serological titres
were below 1:320; this titre corresponds to
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the detection threshold of a recently pub-
lished ORF2 protein-based ELISA (data
not shown) [6].
2.5. Polymerase chain reaction (PCR) 
A PCR technique was used to screen
PCV2 in serum samples from all experi-
mental pigs at all sampling times. In addi-
tion, the PCV1 genome was also screened
from serum samples at day 0 PI. DNA was
extracted from 0.2 mL of serum using a
blood commercial kit (Qiagen Inc.,
Valencia, CA, USA) following the manu-
facturer’s protocol. Established protocols
for PCV2 and PCV1 amplification were
used as previously described [20].
2.6. TaqMan PCR 
To quantify PCV2 DNA in PCR posi-
tive serum samples from 7, 14, 21, 49 and
69 DPI, a real-time fluorescent-probe PCR
was used as previously described [24]. The
assay was performed in duplicate.
2.7. Statistical analysis 
Rectal temperatures of the different
groups were compared with the Statsdi-
rect programme, using variance analysis
with the Kruskal-Wallis test. All other sta-
tistical analysis was performed using the
SAS system [SAS/STAT Users’ Guide:
Statistics, version 8 (SAS Institute Inc.,
Cary, N.C.)]. A mixed linear model [26]
was used to detect significant differences in
the evolution of body weight, serology, and
TaqMan PCR results between groups. A
contingency table test was used to assess
homogeny of both PCV2 inoculated groups
at day 0 PI, by analysing the differences in
the proportion of IPMA titers in serum sam-
ples between PCV2 and PCV2 + ADJ
groups. Afterwards, a generalised linear
model was used to evaluate the differences
in the proportion of PCR positive results
between PCV2 and PCV2 + ADJ groups
throughout the experimental period.
3. RESULTS
3.1. Clinical signs 
Pigs from both PCV2-inoculated groups
had a slight to moderate hyperthermia,
ranging from 40.5 to 41.5 °C, at 5, 16 and
19 DPI (p < 0.05). Moreover, the PCV2 +
ADJ-group had a significantly higher
number (p < 0.05) of pigs with hyperther-
mia (n = 10) compared to the PCV2-group
(n = 2) at 19 DPI. No significant differ-
ences were observed in the evolution of
body weights between the four groups. No
other clinical signs were observed in any of
the pigs during the experimental period.
3.2. Gross and microscopic lesions
Two out of 14 and 7 out of 16 pigs from
PCV2 and PCV2 + ADJ groups, respec-
tively, had a few multifocal white foci in
kidney cortices. No other significant gross
lesions were observed. 
Characteristic PMWS microscopic lesions,
such as lymphocyte depletion and histio-
cytic infiltration, were not found in any of
the pigs at the time of examination (69 DPI).
Only mild to moderate multifocal intersti-
tial nephritis were observed in some pigs
from all groups.
3.3. In situ hybridisation (ISH)
PCV2 nucleic acid was found in the
lymphoid tissues from three pigs from each
PCV2 inoculated group. Scant labelling
was detected in the cytoplasm of follicular
dendritic-like cells of the mesenteric and
inguinal lymph nodes, and tonsil. 
3.4. PCV2 and PCV1 serological results
Seroconversion was first detected at day
21 PI in 10 out of 14 (71.4%) PCV2 inoc-
ulated pigs and in 15 out of 16 (93.7%)
PCV2 + ADJ inoculated pigs, with titres
ranging from 1:320 to 1:5120. Three pigs
from the PCV2-group seroconverted after
day 35 PI. No differences were observed
in the antibody titres evolution between
Experimental inoculation of PCV2 and a vaccine adjuvant in conventional pigs 87
both inoculated groups. In both inoculated
groups PCV2 antibody titres increased
throughout the experimental period (Fig. 1).
By the end of the experiment, most pigs had
high antibody titres, ranging from 1:5120 to
1:20480. Neither control pigs nor the pigs
inoculated with the adjuvant showed sero-
conversion to PCV2 throughout the exper-
imental period. Five out of 14 PCV2 inoc-
ulated and 6 out of 16 PCV2 + ADJ
inoculated pigs seroconverted to PCV1,
with titres ranging from 1:320 to 1:1280,
between days PI 21 and 69.
3.5. Serum PCV1 and PCV2 PCR
No PCV2 amplification was detected in
the serum samples from both control groups
during the whole experimental period,
nor in both PCV2-inoculated groups before
challenge. The onset of viremia was detected
in both PCV2-inoculated groups between
days 7 and 21 PI in a high proportion of the
pigs. The percentages of positive serum
samples are represented in Figure 2. Over-
all, no significant differences were observed
in the dynamics of PCV2 viremia between
the PCV2 and PCV2 + ADJ groups. PCV2
DNA detection persisted (intermittently or
continuously) at least until 69 days PI in
most pigs. Viral DNA was undetectable in
two pigs from the PCV2-group, and sporad-
ically detected in four pigs from both PCV2
inoculated groups. 
The PCV1 genome was not found in any
of the samples at day 0 PI. 
3.6. Serum PCV2 TaqMan PCR
The results are summarised in Figure 3.
No significant differences were observed in
the serum viral load between PCV2 and
PCV2 + ADJ groups. A peak of the virus
load was observed between days 14 and
21 PI, in both PCV2-inoculated groups. 
4. DISCUSSION
The present study was designed to eval-
uate the effect of a commercial vaccine
adjuvant on the potential development of
PMWS in 8 to 9-week-old conventional
pigs. The age of the pigs at inoculation was
chosen based on a low level of maternal
antibodies, which coincided with the typi-
cal age presentation of PMWS under field
conditions [22]. 
Under the present experimental condi-
tions, no potentiation effect was observed
Figure 1. Dynamics of anti-PCV2 serum titres (LS Means) of pigs from the four experimental
groups. LS Means Log 10 titres are equivalent to IPMA titres expressed as the inverse of the
maximum dilution with reaction: 0 = negative; 1.3 = 1/20; 1.9 = 1/80; 2.5 = 1/320; 3.1 = 1/1280;
3.7 = 1/5120; 4.3 = 1/20480). Vertical bars correspond to ± 1 SD. 
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by the use of the vaccine adjuvant in PCV2
replication and development of PMWS. All
PCV2-inoculated pigs developed a subclin-
ical infection, as demonstrated by serocon-
version to PCV2 and the long-term viremia
at least until day 69 PI. No characteristic
PMWS lesions [8, 23] were found at the
experimental termination day, despite the
occasional presence of the viral genome in
some lymphoid tissues. The only clinical
evidence of the viral infection was an inter-
mittent hyperthermia, between days 16 and
19 PI, which coincided with the onset of
viremia and the highest viral load in the
serum, which is in concordance with the
results from other PCV2 experimental trials
[7, 24]. 
The serological profile observed in both
PCV2 inoculated groups was similar, and
was in agreement with those from other
experimental trials, with an increase of anti-
body titres occurring after 2 weeks PI,
shortly after viremia detection [7, 17, 19].
Viremia coexisted with high antibody titres
until the end of the experiment, which
suggests that PCV2 can evade a specific
immune response, or alternatively, an
effective immune response was of slow
development, as suggested by other authors
[22]. On the contrary, seroconversion to
Figure 2. Percentage of positive PCV2 serum samples in both PCV2 inoculated groups (PCV2 and
PCV2 + ADJ groups) throughout the experimental sampling period using PCR. 
Figure 3. PCV2 genome mean
coded load (Log 10) using TaqMan
PCR in positive PCR serum samples
both in the PCV2 and PCV2 +
adjuvant (ADJ) group at intervals
after inoculation.
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PCV1 was observed in a proportion of pigs;
these results were not surprising, since it
is well known that serological cross-reac-
tion between PCV1 and PCV2 exists [21].
In fact, this serological cross-reactivity
between both porcine circoviruses has been
observed in pigs experimentally infected
with PCV2, associated to the development
of seroneutralising antibodies [19].
Viremia and seroconversion were ana-
lysed and compared over time using a gen-
eralised and mixed linear model, but no sig-
nificant differences were observed between
the PCV2-adjuvant pigs versus the PCV2
pigs. In addition, no significant differences
were observed in PCV2 viremia quantifica-
tion, thus excluding any potentiation effect
on viral replication by the adjuvant in this
particular trial. It is known that PMWS
affected pigs have a higher viral load than
subclinically PCV2 infected pigs [12, 13,
15, 16, 24]. Therefore, it has been proposed
that the use of products that stimulate the
immune system, such as vaccines or non-
specific immunostimulators, may potenti-
ate PCV2 replication leading to PMWS [4,
12, 14]. In the present study, the use of a
commercial adjuvant in PCV2 infected pigs
did not result in PMWS, suggesting that not
all adjuvants used in commercial vaccines
may be capable of triggering the mecha-
nisms that potentiate PCV2 replication and
generate disease. Therefore, the principle of
immunostimulation may not be applicable
to all different swine production systems,
experimental conditions and/or host char-
acteristics, as suggested by other authors
[15]. The latter study demonstrated that
KLH/ICFA is not necessary for the induc-
tion of PMWS in 3 week-old SPF pigs. In
addition, the same adjuvant does not trigger
any clinical effect when applied locally in
the neck of gnotobiotic PCV2 infected pig-
lets [12]. The results of the abovementioned
studies are in full agreement with the results
of the present study. Therefore, the role of
immune stimulation as an important key
point in the outcome of naturally occurring
PMWS remains to be elucidated. 
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